Experimental drug aims to tame deadly COVID-19 inflammation
NCT ID NCT04469621
Summary
This early-stage study tested an experimental drug designed to calm the dangerous overactive immune response (hyperinflammation) seen in severe COVID-19. It involved 68 adults hospitalized with severe COVID-19 who were given the drug or a placebo. The main goal was to see if the drug safely reduced inflammation markers and helped patients breathe better, potentially controlling the disease's worst effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONA VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number 0320001
Caba, 1430, Argentina
-
Investigational Site Number 0760001
São José do Rio Preto, 15090-000, Brazil
-
Investigational Site Number 0760002
São Paulo, 04321-120, Brazil
-
Investigational Site Number 0760003
Porto Alegre, 90035 003, Brazil
-
Investigational Site Number 1520001
Santiago, 750-0691, Chile
-
Investigational Site Number 1520002
Talca, 3460001, Chile
-
Investigational Site Number 1520003
Santiago, 8900085, Chile
-
Investigational Site Number 4840001
Monterrey, 64460, Mexico
-
Investigational Site Number 6430001
Moscow, 111539, Russia
-
Investigational Site Number 6430002
Moscow, 123182, Russia
Conditions
Explore the condition pages connected to this study.